Company news

Sandoz Group Ltd news in 2025

Sandoz Group Ltd's news releases, calls and decks from 2025, newest first.

View company

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis

November 17, 2025

Sandoz Canada launches PrSandoz® Sacubitril-Valsartan, expanding access to heart failure treatments

October 1, 2025

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

September 24, 2025

Sandoz welcomes Quebec government support for Boucherville plant modernization project

August 27, 2025

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

August 12, 2025

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

August 7, 2025

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

July 30, 2025

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

July 1, 2025

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

June 2, 2025

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

May 21, 2025

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

April 30, 2025

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

April 29, 2025

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

April 15, 2025

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

April 14, 2025

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

April 14, 2025

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

March 31, 2025

Sandoz reports strong FY 2024 results and Q4 2024 sales

March 5, 2025

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

February 24, 2025

Calls in 2025

Decks in 2025